AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mestdagh, M.
Right arrow Articles by Van den Eeckhout, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mestdagh, M.
Right arrow Articles by Van den Eeckhout, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 1999, p. 2317-2319, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Relationship between Pyrazinamide Resistance, Loss of Pyrazinamidase Activity, and Mutations in the pncA Locus in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis

M. Mestdagh,1 P. A. Fonteyne,2 L. Realini,2 R. Rossau,3 G. Jannes,3 W. Mijs,3 K. A. L. De Smet,3 F. Portaels,2 and E. Van den Eeckhout1,*

Laboratory for Pharmaceutical Biotechnology, FFW, University of Ghent, 9000 Ghent,1 Unit of Mycobacteriology, Institute of Tropical Medicine, 2000 Antwerp,2 and Innogenetics n.v., 9052 Ghent,3 Belgium

Received 25 March 1999/Returned for modification 16 June 1999/Accepted 13 July 1999

Sixty-two Mycobacterium tuberculosis isolates were tested for pyrazinamidase activity, and their pyrazinamide susceptibility was determined by the radiometric method. Sequencing of pncA genes in the 23 resistant strains revealed mutations in 16 pyrazinamidase-negative strains, 11 of which had not been previously described. Six isolates containing wild-type pncA might possess alternative resistance mechanisms.

* Corresponding author. Mailing address: Laboratory for Pharmaceutical Biotechnology, FFW, University of Ghent, Harelbekestraat 72, 9000 Ghent, Belgium. Phone: 32-9.264.80.52. Fax: 32-9.220.66.88. E-mail: Elfriede.VandenEeckhout{at}rug.ac.be.

Antimicrobial Agents and Chemotherapy, September 1999, p. 2317-2319, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.